IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
On February 16, 2017, Imprimis Pharmaceuticals, Inc. (the
Company) issued a press release which contained certain
preliminary unaudited sales estimates of the companys
ophthalmology business for the fourth quarter ended December 31,
2016. The press release is being furnished as Exhibit 99.1 to
this Current Report on Form 8-K.
The information furnished under this Item 2.02 of this Current
Report on Form 8-K, including Exhibit 99.1, shall not be deemed
to be filed for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that Section. The information in
this Item 2.02, including Exhibit 99.1, shall not be deemed
incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except to the
extent it is specifically incorporated by reference but
regardless of any general incorporation language in such filing.
The information furnished under this Item 2.02 of this Current
Report on Form 8-K, including Exhibit 99.1, shall not be deemed
to constitute an admission that such information or exhibit is
required to be furnished to Regulation FD or that such
information or exhibit contains material information that is not
otherwise publicly available. In addition, the Company does not
assume any obligation to update such information or exhibit in
the future.
Item 7.01. Regulation FD Disclosure
Attached as Exhibit 99.2 to this Item 7.01 is a presentation that
is being used by the management of Imprimis Pharmaceuticals, Inc.
(the Company) at investor conferences and at meetings describing
the Company.
The information contained in Item 7.01 of this report and in
Exhibit 99.2 shall not be deemed filed for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such a
filing.
Item 9.01. Financial Statements and Exhibits
| (d) | Exhibits |
| 99.1 |
Press release dated February 16, 2017 issued by Imprimis Pharmaceuticals, Inc. |
| 99.2 |
Imprimis Pharmaceuticals, Inc. presentation dated February 2017 |
About IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY)
Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas. IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Recent Trading Information
IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) closed its last trading session up +0.36 at 2.79 with 459,902 shares trading hands.
